Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Reata Stock Holders Approved the Firm's Merger with Biogen

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary results indicate that the stockholders of the firm have voted to approve the Company’s previously announced acquisition (the “Merger”) by Biogen ( BIIB )...

September 21, 2023

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

Pliant Therapeutics in the NEWS Treating Primary Sclerosing Cholangitis Pliant Therapeutics ( PLRX ) today announced positive data from a Phase 2a INTEGRIS-PSC clinical trial of the firm’s product bexotegrast in patients with primary sclerosing cholangitis ( PSC ) and...

September 26, 2023

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

Neurocrine Biosciences Announcement Today, Neurocrine Biosciences ( NBIX ) announced positive top-line data from the Phase 3 CAHtalyst™ Pediatric Study evaluating the safety, efficacy and tolerability of the firm’s product crinecerfont treating children and adolescents with classic congenital adrenal hyperplasia...

October 5, 2023

Akero Therapeutics' October 10, 2023 Press Release

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip Akero...

October 10, 2023

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

Intellia Therapeutics' NTLA-2001 Intellia Therapeutics' NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. Today, October 18, 2023, Intellia Therapeutics ( NTLA ) announced that the U.S. Food and Drug Administration...

October 18, 2023

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Beam Therapeutics in the NEWS Beam Therapeutics ( BEAM ) announced that Eli Lilly ( LLY ) has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics (Verve) , including Beam’s opt-in rights to...

October 31, 2023

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

CRISPR Therapeutics and Vertex Pharmaceuticals NEWS CRISPR Therapeutics ( CRSP ) announced the completion of the U.S. Food and Drug Administration’s ( FDA ) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of...

November 1, 2023

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

ImmunoGen in the NEWS Immunogen ( IMGN ) - a developer of antibody-drug conjugates ( ADCs ) for cancer treatment , today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. From...

November 2, 2023

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

CRISPR Therapeutics Data Presentation Announcement CRISPR Therapeutics ( CRSP ) today announced preclinical data from the Company’s investigational programs for the treatment of cardiovascular disease at the American Heart Association ( AHA ) Scientific Sessions 2023. The data will be...

November 6, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease and Transfusion Dependent Beta Thalassemia Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP ) today announced that the United Kingdom (U.K.) Medicines...

November 16, 2023

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024